Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Sandoz completes acquisition of ranibizumab biosimilar
Sandoz completes acquisition of ranibizumab biosimilar
Sandoz completes acquisition of ranibizumab biosimilar
Submitted by
admin
on March 4, 2024 - 11:52pm
Source:
Healio
News Tags:
Sandoz
ranibizumab
Coherus Biosciences
Cimerli
Headline:
Sandoz completes acquisition of ranibizumab biosimilar
snippet:
Sandoz has acquired Cimerli, a ranibizumab biosimilar.
The transaction includes the full Cimerli business for $170 million.
Do Not Allow Advertisers to Use My Personal information
